Scalable, cGMP-Ready AAV & LV Platform Processes

IDT Biologika’s AAV and LV platform processes are scalable, cGMP-ready and may accelerate the process development timeline. They are applicable for all standard AAV serotypes and LVV variants.

With sites in Europe and the USA, IDT Biologika offers both the flexibility and redundant capabilities that reduce manufacturing complexities often found in the market. Our expertise and capabilities allowed us to produce our own HEK293 production cell lines utilizing a wide variety of upstream platforms including iCellis, Cell Stacks, Univercells, and Stirred-Tank Reactors. Along with our own AAV and LLV platforms, we offer the flexibility to take on your project as a tech transfer for clinical or commercial supply. Our upstream and downstream suspension or adherent capabilities range from 50 L – 2,000 L, and up to 2 x 500 sqm, respectively. All Cell and Gene therapy specific Quality Control Testing can be done in-house.